{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "currency": "EUR", "market": "gb_market", "esgPopulated": false, "gmtOffSetMilliseconds": 3600000, "exchange": "LSE", "longName": "Transgene SA", "shortName": "TRANSGENE SA TRANSGENE ORD SHS", "regularMarketPrice": 1.802, "regularMarketChangePercent": 1.8079133, "messageBoardId": "finmb_386045", "marketState": "POSTPOST", "fiftyTwoWeekHighChangePercent": -0.316129, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 2.635, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 1.802, "fiftyTwoWeekRange": "0.0 - 2.635", "fiftyTwoWeekHighChange": -0.83299994, "epsTrailingTwelveMonths": -0.214, "sharesOutstanding": 62275900, "bookValue": 0.379, "fiftyDayAverage": 1.977974, "fiftyDayAverageChange": -0.17597401, "fiftyDayAverageChangePercent": -0.088966794, "twoHundredDayAverage": 2.042911, "twoHundredDayAverageChange": -0.240911, "twoHundredDayAverageChangePercent": -0.11792535, "marketCap": 1123975, "priceToBook": 4.754617, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1225872000000, "priceHint": 4, "regularMarketChange": 0.032000065, "regularMarketTime": 1683790545, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 134400, "regularMarketPreviousClose": 1.77, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "EUR", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 603, "averageDailyVolume10Day": 456, "symbol": "0OCQ.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "400, boulevard Gonthier d\u2019Andernach", "address2": "Parc d\u2019innovation CS80166 Cedex", "city": "Illkirch-Graffenstaden", "zip": "67405", "country": "France", "phone": "33 3 88 27 91 00", "fax": "33 3 88 27 91 11", "website": "https://www.transgene.fr", "industry": "", "sector": "", "longBusinessSummary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "fullTimeEmployees": 146, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hedi Ben Brahim", "age": 41, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 315000, "fmt": "315k", "longFmt": "315,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jean-Philippe  Del", "age": 41, "title": "VP & CFO", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Eric  Quemeneur Ph.D.", "age": 57, "title": "Exec. VP & Chief Scientific Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elisabetta  Castelli", "title": "Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Felitti J.D., LLM", "age": 52, "title": "VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lucie  Larguier", "title": "Director of Corp. Communications & IR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Gaelle  Stadtler", "age": 39, "title": "VP & Director of HR", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Maud  Brandely-Talbot M.D., Ph.D.", "age": 68, "title": "VP of Medical Affairs & Chief Medical Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steven H. Bloom R.Ph.", "age": 60, "title": "VP & Chief Bus. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kaidre  Bendjama", "title": "Project Leader of Personalized Cancer Vaccines", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}